Q4 FY26 results analysis · May 26, 2026

Jubilant Ingrevia Ltd Q4 FY26 Results Analysis: PAT Jumps 16.7%, Specialty Margin Expands 310 bps

+16.7%PAT year on year, Rs. 86.44 Cr
Cofacto ResearchPublished May 26, 20262 min readNeutral read
Quick summary

Jubilant Ingrevia Ltd's Q4 FY26 numbers came in mixed, with revenue of Rs. 1,178.65 Cr (+12.10% YoY) and PAT growth of +16.72% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateMay 26, 2026
QuarterQ4 FY 2025-2026
Revenue (Q4)Rs. 1,178.65 Cr (+12.10% YoY)
PAT (Q4)Rs. 86.44 Cr (+16.72% YoY)
EBITDA margin13.80% (-16 bps YoY)
EPS (Q4)Rs. 5.47 (+16.63% YoY)
Market capRs. 11,523.78 Cr
CMPRs. 723.10

Quarter Snapshot

JUBLINGREA delivered a strong Q4 with 12.1% revenue and 16.7% PAT growth, along with 310 bps margin expansion in specialty chemicals and a turnaround in the chemical intermediates segment. However, full-year results lagged management's aspirational targets: revenue grew only 5%, EBITDA growth was below 20% CAGR, and capex was 48% below guidance. The financial strength — evidenced by 1.89x cash conversion and 58% FCF growth — is positive, but the strategic targets appear aspirational without a significant growth acceleration.

Key Investment Insights

Key Positives

  • Consolidated revenue grew 12.1% YoY to Rs.117,865 Lakhs in Q4 FY26.
  • Consolidated PAT grew 16.7% YoY to Rs.8,644 Lakhs.
  • Specialty Chemicals FY26 EBIT margin expanded 310 bps to 21.2%.
  • Chemical Intermediates turned from a loss of Rs.191 Lakhs (Q4 FY25) to a profit of Rs.551 Lakhs (Q4 FY26).
  • Cash from operations was 1.89x PAT at Rs.52,427 Lakhs.
  • Free cash flow of Rs.22,491 Lakhs was up 58% YoY.
  • Net debt declined 10.1% to Rs.591 Cr; debt-to-equity improved to 0.19x from 0.22x.

Risk Factors

  • Revenue growth of 5.0% for full FY26 is below the aspirational 3x by FY'30 target.
  • Nutrition & Health Solutions EBIT margin declined to 10.1% in FY26 from 11.7% in FY25, well below the 16-18% target.
  • FY26 capex of Rs.310 Cr was 48% below the stated guidance of ~Rs.600 Cr.
  • Chemical Intermediates FY26 EBIT margin compressed to 1.14% from 3.68% in FY25.
  • Strong revenue growth in Q4 partly driven by Rs.2,301 Lakhs inventory build, which temporarily supported margins.
  • Company's long-term aspirational targets (3x revenue, 4x EBITDA by FY'30) appear very difficult based on current 5% revenue and 9% EBITDA growth rates.

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.